Targeting Cbx3/HP1γ Induces LEF-1 and IL-21R to Promote Tumor-Infiltrating CD8 T-Cell Persistence

Autor: Phuong T. Le, Ngoc Ha, Ngan K. Tran, Andrew G. Newman, Katharine M. Esselen, John L. Dalrymple, Eva M. Schmelz, Avinash Bhandoola, Hai-Hui Xue, Prim B. Singh, To-Ha Thai

Publikováno v: Frontiers in Immunology, Vol 12 (2021)

Immune checkpoint blockade (ICB) relieves CD8+ T-cell exhaustion in most mutated tumors, and TCF-1 is implicated in converting progenitor exhausted cells to functional effector cells. However, identifying mechanisms that can prevent functional senesc

Externí odkaz: https://doaj.org/article/5046e0f6247a45a98a6ec88b1cfc1444

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

CBX3/HP1γ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma

Autor: Wancong Zhang, Shijie Tang, Anna Kan, Huayong Zhang, Jianda Zhou, Jiasheng Chen, Xiaoping Zhong

Publikováno v: Aging (Albany NY)

HP1γ, encoded by CBX3, is associated with cancer progression and patient prognosis. However, the prognostic value and functions of CBX3/HP1γ in hepatocellular carcinoma (HCC) remain unclear. Here, we performed a bioinformatics analysis using the On

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc094d9f7614f908f90b0031bda420c6
http://europepmc.org/articles/PMC6710055

CBX3/HP1γ is upregulated in tongue squamous cell carcinoma and is associated with an unfavorable prognosis

Autor: Xuan Su, Xiaoyan Fu, Ankui Yang, Huayong Zhang

Publikováno v: Experimental and Therapeutic Medicine

Increased expression of CBX3/HP1γ, a core component of heterochromatin protein 1, has recently proved to be involved in human tumorigenesis and patient prognosis. The present study aimed to investigate the expression of CBX3/HP1γ and its clinicopat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662462a6752b56f5afd8646130fcbd95
https://pubmed.ncbi.nlm.nih.gov/29731822

Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8 ⁺ T cells.

Autor: Sun M; Beth Israel Deaconess Medical Center, Harvard Medical School, Department of Pathology, Boston, MA 02215, USA., Ha N; Beth Israel Deaconess Medical Center, Harvard Medical School, Department of Pathology, Boston, MA 02215, USA.; Department of Neurobiology and Anatomy, Drexel University, College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA., Pham DH; Beth Israel Deaconess Medical Center, Harvard Medical School, Department of Pathology, Boston, MA 02215, USA.; Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA., Frederick M; Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL, 33458, USA., Sharma B; Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02215, USA., Naruse C; Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan., Asano M; Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan., Pipkin ME; Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL, 33458, USA., George RE; Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02215, USA.; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA., Thai TH; Beth Israel Deaconess Medical Center, Harvard Medical School, Department of Pathology, Boston, MA 02215, USA.

Publikováno v: Scientific reports [Sci Rep] 2017 Feb 21; Vol. 7, pp. 42888. Date of Electronic Publication: 2017 Feb 21.